Product Description
Opiant is developing drinabant (OPNT004), a high affinity, CB-1 antagonist for the treatment of Acute Cannabinoid Overdose (ACO). The rationale for using drinabant to treat ACO is based on multiple studies demonstrating that CB-1 antagonists like drinabant compete with agonists (THC and SCs) for CB-1 receptors, terminating their pharmacological actions. (Sourced from: https://www.opiant.com/products-pipeline/pipeline/opnt004-drinabant-cb-1-antagonist/)
Mechanisms of Action: CB1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Obesity|Dyslipidemia|Schizophrenia|Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CONNECT | P2 |
Terminated |
Schizophrenia |
2009-09-01 |
|
| 2006-002317-12 | P2 |
Completed |
Alzheimer Disease |
2007-07-12 |
|
| ACT10019 | P2 |
Completed |
Alzheimer Disease |
2007-07-01 |
|
| DRI6412 | P2 |
Completed |
Obesity|Dyslipidemia |
2007-06-01 |